Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
Authors
Keywords
-
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 38, Issue S1, Pages E2412-E2418
Publisher
Wiley
Online
2016-02-03
DOI
10.1002/hed.24367
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HRG-β1-driven ErbB3 signaling induces epithelial–mesenchymal transition in breast cancer cells
- (2013) Jinkyoung Kim et al. BMC CANCER
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
- (2013) A. P. Garner et al. CANCER RESEARCH
- High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
- (2013) David S. Shames et al. PLoS One
- Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
- (2013) Ferdows Ather et al. PLoS One
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- (2011) Timothy R. Wilson et al. CANCER CELL
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
- (2011) Mikiko Takikita et al. Journal of Translational Medicine
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR
- (2010) Chetana Basavaraj et al. CANCER BIOLOGY & THERAPY
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas
- (2010) SD Silva et al. ORAL DISEASES
- The upgraded role of HER3 and HER4 receptors in breast cancer
- (2009) Angelos K. Koutras et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict ForIn VitroSensitivity to Gefitinib
- (2009) D. Mark Hickinson et al. CTS-Clinical and Translational Science
- EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
- (2008) Qichun Wei et al. ANNALS OF SURGICAL ONCOLOGY
- The ERBB3 receptor in cancer and cancer gene therapy
- (2008) G Sithanandam et al. CANCER GENE THERAPY
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
- ERBB receptors in developing, dysplastic and malignant oral epithelia
- (2007) J. Rautava et al. ORAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started